Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Participants With Cholestatic Pruritus

NCT06553768 is registered in ClinicalTrials.gov with Mirum Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06553768
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06553768 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Participants With Cholestatic Pruritus
Lead sponsor
Mirum Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 14, 2024
Completion date
February 28, 2027
Enrollment
90 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

cholestatic liver disease (except algs, pfic, pbc and psc)